NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Forecast & News

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) issued its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. View Brainstorm Cell Therapeutics' Earnings History.

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Brainstorm Cell Therapeutics.

1 brokerages have issued 12 month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 42.2% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics.

News headlines about BCLI stock have been trending extremely negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Brainstorm Cell Therapeutics earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 828,200 shares, an increase of 11.7% from the January 15th total of 741,600 shares. Based on an average daily trading volume, of 107,600 shares, the short-interest ratio is presently 7.7 days. Currently, 4.4% of the company's stock are sold short. View Brainstorm Cell Therapeutics' Current Options Chain.

Some companies that are related to Brainstorm Cell Therapeutics include Compugen (CGEN), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), PDL BioPharma (PDLI), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Cabaletta Bio (CABA), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO) and Novavax (NVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix Biotherapeutics (PLX), Sangamo Therapeutics (SGMO), IsoRay (ISR), Mellanox Technologies (MLNX), Ionis Pharmaceuticals (IONS), Caladrius Biosciences (CLBS) and Abeona Therapeutics (ABEO).

Brainstorm Cell Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.48%), Raymond James & Associates (0.54%), Bank of America Corp DE (0.10%), CFO4Life Group LLC (0.05%) and Tower Research Capital LLC TRC (0.05%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View Institutional Ownership Trends for Brainstorm Cell Therapeutics.

BCLI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Raymond James & Associates, CFO4Life Group LLC, Tower Research Capital LLC TRC and Bank of America Corp DE. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View Insider Buying and Selling for Brainstorm Cell Therapeutics.

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BCLI stock can currently be purchased for approximately $6.33.

Brainstorm Cell Therapeutics has a market capitalization of $143.12 million. The biotechnology company earns $-13,950,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.View Additional Information About Brainstorm Cell Therapeutics.

The official website for Brainstorm Cell Therapeutics is http://www.brainstorm-cell.com/.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]